Ingredients Vit C, Vit B1, B2, B3, B5, B6, B12, Multiple Specialised Ingredients, Magnesium & Zinc
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists [see Adverse Reactions (6)]
N Engl J Med 2025;393:1796-1806 [9] Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial, December 2025: Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company [10] Fourth High-level Meeting of the UN General Assembly on the prevention and control of NCDs and the promotion of mental health and wellbeing (HLM4), September 2025: [11] Thousands of patients from Scotlands poorest areas to benefit from landmark UK government-funded obesity study, November 2025: Thousands of patients from Scotlands poorest areas to benefit from landmark UK government-funded obesity study - GOV.UK [12] Non-Traditional Channels: The Compounded GLP-1 Market
Potential Drug Interactions If you are already taking medication for high blood pressure, adding a GLP-1 medication can create a double effect. Your existing blood pressure medication might become too powerful as you lose weight and as the semaglutide begins to lower your pressure naturally
Importantly, GLP-1 receptor agonists are not indicated for type 1 diabetes or diabetic ketoacidosis, and should not be co-prescribed with DPP-4 inhibitors (such as sitagliptin or linagliptin)
1-complete loss of tail function
